EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Beyond β-Lactams: Defining the Role of Eravacycline in Multidrug-Resistant and Metallo-β-Lactamase-Producing Infections

Jacob M Keck

Antibiotics · 18.05.2026 · 15 (5) · 503

DOI: 10.3390/antibiotics15050503 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antibiotics, online erschienen am 18.05.2026. Verfasst von Jacob M Keck. Beteiligte Einrichtung: Department of Pharmacy, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR 72205, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 209 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The global spread of multidrug-resistant (MDR) Gram-negative pathogens has significantly narrowed therapeutic options for serious infections. MDR organisms frequently harbor multiple resistance mechanisms, such as β-lactamases and non-β-lactam determinants, which limit the activity of many β-lactam/β-lactamase inhibitor combinations and complicate the clinical utility of newer agents such as cefiderocol and aztreonam–avibactam. These challenges highlight the need for mechanistically distinct, non-β-lactam therapies capable of maintaining activity in MDR settings. Eravacycline is a fully synthetic fluorocycline antibiotic that inhibits bacterial protein synthesis through high-affinity binding to the 30S ribosomal subunit, a mechanism unaffected by β-lactamase-mediated resistance. Structural modifications at key positions confer stability against common tetracycline resistance mechanisms, including efflux pumps and ribosomal protection proteins. In vitro surveillance studies consistently demonstrate potent activity against a broad range of MDR Gram-negative pathogens, notably carbapenem-resistant Enterobacterales and isolates harboring metallo-β-lactamases. The clinical efficacy and safety of eravacycline have been established in pivotal Phase 3 trials for complicated intra-abdominal infections. Although highly resistant phenotypes were underrepresented in these trials, emerging real-world data describe off-label use in MDR Gram-negative infections, often as salvage or step-down therapy. These experiences suggest acceptable clinical outcomes and favorable tolerability in complex, high-risk patients. This review synthesizes mechanistic, microbiologic, pharmacologic, and clinical evidence supporting eravacycline’s potential role in the management of MDR Gram-negative infections.

Schlagwörter

Stichwörter der Autor:innen

New Delhi metallo-β-lactamase (NDM)eravacyclinemultidrug-resistant (MDR) pathogens

Autor:innen und Institutionen

  • Department of Pharmacy, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR 72205, USA.

Zitieren

APA

Keck, J. M. (2026). Beyond β-Lactams: Defining the Role of Eravacycline in Multidrug-Resistant and Metallo-β-Lactamase-Producing Infections. Antibiotics, 15(5), 503. https://doi.org/10.3390/antibiotics15050503

Vancouver

Keck JM. Beyond β-Lactams: Defining the Role of Eravacycline in Multidrug-Resistant and Metallo-β-Lactamase-Producing Infections. Antibiotics. 2026;15(5):503. doi:10.3390/antibiotics15050503

BibTeX
@article{Keck2026,
  author = {Keck, Jacob M},
  title = {Beyond β-Lactams: Defining the Role of Eravacycline in Multidrug-Resistant and Metallo-β-Lactamase-Producing Infections},
  journal = {Antibiotics},
  year = {2026},
  volume = {15},
  number = {5},
  pages = {503},
  doi = {10.3390/antibiotics15050503}
}
Kostenlos starten →